Semaglutide: Not a Universal Obesity Solution

The OMS (World Health Association) has already placed semaglutide among essential drugs to treat obesity, a step that puts pressure on social works to expand coverage.

Even so, Nutrition graduate Gisela Manucci (MP No. 1,116) asks to stop the impulse and look at the big picture: Semaglutide is not for every patient and should only be used under medical indication.

READ MORE ►Obesity: what are the new WHO recommendations on injectable weight loss medications

In dialog with AIRE, Manucci clarifies that all the available evidence arises from studies in peopel with severe pathologies such as severe obesity, morbid obesity and patients with metabolic comorbidities such as diabetes or cardiovascular disease. There are no studies in people who are simply looking to lose a few kilos.

“That is not the correct use,” the specialist maintains without hesitation when asked about the effectiveness of the injection for weight loss. And she points out that the problem is twofold. On the one hand, a culture that continues to look for instant solutions. On the other hand, the presence of professionals who indicate it without the necessary clinical support.

The B side of the “ideal weight” drug

Adverse effects are far from being a detail. The most frequent are felt in the gastrointestinal system: nausea, vomiting and diarrhea. Headaches or migraines are also common.